Humacyte, Inc. (HUMA)
0.5856
+0.01
(+1.83%)
USD |
NASDAQ |
Sep 18, 16:00
0.5845
0.00 (0.00%)
After-Hours: 20:00
Humacyte Price to Book Value : 5.204 for Sept. 18, 2026
Price to Book Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Price to Book Value Data
| Date | Value |
|---|---|
| September 18, 2026 | 5.204 |
| September 17, 2026 | 5.111 |
| September 16, 2026 | 5.065 |
| September 15, 2026 | 4.902 |
| September 14, 2026 | 4.985 |
| September 11, 2026 | 5.044 |
| September 10, 2026 | 5.040 |
| September 09, 2026 | 5.145 |
| September 08, 2026 | 5.287 |
| September 04, 2026 | 5.376 |
| September 03, 2026 | 5.296 |
| September 02, 2026 | 5.302 |
| September 01, 2026 | 5.069 |
| August 31, 2026 | 5.344 |
| August 28, 2026 | 5.777 |
| August 27, 2026 | 6.156 |
| August 26, 2026 | 6.057 |
| August 25, 2026 | 6.231 |
| August 24, 2026 | 5.885 |
| August 21, 2026 | 5.707 |
| August 20, 2026 | 6.055 |
| August 19, 2026 | 6.531 |
| August 18, 2026 | 5.169 |
| August 17, 2026 | 4.982 |
| August 14, 2026 | 5.375 |
| Date | Value |
|---|---|
| August 13, 2026 | 4.888 |
| August 12, 2026 | 5.910 |
| August 11, 2026 | 6.309 |
| August 10, 2026 | 6.616 |
| August 07, 2026 | 6.382 |
| August 06, 2026 | 6.306 |
| August 05, 2026 | 6.476 |
| August 04, 2026 | 6.329 |
| August 03, 2026 | 6.126 |
| July 31, 2026 | 5.806 |
| July 30, 2026 | 5.968 |
| July 29, 2026 | 5.550 |
| July 28, 2026 | 5.605 |
| July 27, 2026 | 5.990 |
| July 24, 2026 | 5.552 |
| July 23, 2026 | 5.675 |
| July 22, 2026 | 5.728 |
| July 21, 2026 | 5.961 |
| July 20, 2026 | 5.831 |
| July 17, 2026 | 5.907 |
| July 16, 2026 | 5.862 |
| July 15, 2026 | 6.057 |
| July 14, 2026 | 6.285 |
| July 13, 2026 | 6.142 |
| July 10, 2026 | 6.165 |
Price to Book Ratio Definition
Price to book value is a valuation ratio that is measured by stock price / book value per share. The book value is essentially the tangible accounting value of a firm compared to the market value that is shown.
Price to Book Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Price to Book Value Benchmarks
| Amgen, Inc. | 17.84 |
| Altimmune, Inc. | 1.333 |
| Protalix Biotherapeutics, Inc. | 3.035 |
| Taysha Gene Therapies, Inc. | 4.217 |
| Agenus, Inc. | -- |
Price to Book Value Related Metrics
| PS Ratio | 53.64 |
| PEG Ratio | -0.165 |
| Price | 0.5856 |
| Earnings Yield | -83.61% |
| Market Cap | 162.68M |
| PEGY Ratio | -0.165 |